Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 19, 2014, Pages

  Tang, Xian Chun ^a   Agnihothram, Sudhakar S ^b   Jiao, Yongjun ^a   Stanhope, Jeremy ^a   Graham, Rachel L ^b   Peterson, Eric C ^a   Avnir, Yuval ^a   Tallarico, Aimee St Clair ^a   Sheehan, Jared ^a   Zhu, Quan ^a   Baric, Ralph S ^b,c   Marasco, Wayne A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

Biodefense; Emerging pathogen; Humoral immunity; IGHV1 69; Zoonosis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; PROTEOLIPOSOME; VIRUS ANTIBODY; VITRONECTIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY DETECTION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; CORONAVIRUS; DISSOCIATION CONSTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EVOLUTIONARY ADAPTATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYDROGEN BOND; IC 50; IMMUNOTHERAPY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL LINE; VIRUS ATTACHMENT; VIRUS MUTATION; VIRUS NEUTRALIZATION;

BIODEFENSE; EMERGING PATHOGEN; HUMORAL IMMUNITY; IGHV1-69; ZOONOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOLOGICAL EVOLUTION; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; PHYLOGENY; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL VACCINES; ZOONOSES;

EID: 84900515662     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402074111     Document Type: Article

References (60)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814-1820.
2. Breban R, Riou J, Fontanet A (2013) Interhuman transmissibility of Middle East respiratory syndrome coronavirus: Estimation of pandemic risk. Lancet 382(9893): 694-699.
3. Health Protection Agency (HPA) UK Novel Coronavirus Investigation team (2013) Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 18(11):20427.
4. Cotten M, et al. (2014) Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio 5(1):e01062-e01013.
5. Li W, et al. (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24(8):1634-1643.
6. Chinese SARS Molecular Epidemiology Consortium (2004) Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303(5664): 1666-1669.
7. Annan A, et al. (2013) Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 19(3):456-459.
8. Anthony SJ, et al. (2013) Coronaviruses in bats from Mexico. J Gen Virol 94(Pt 5): 1028-1038.
9. Woo PC, et al. (2006) Molecular diversity of coronaviruses in bats. Virology 351(1): 180-187.
10. Memish ZA, et al. (2013) Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 19(11):1819-1823.
11. Perera RA, et al. (2013) Seroepidemiology for MERS coronavirus using micro-neutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 18(36):20574.
12. Reusken CB, et al. (2013) Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study. Lancet Infect Dis 13(10):859-866.
13. Haagmans BL, et al. (2014) Middle East respiratory syndrome coronavirus in dromedary camels: An outbreak investigation. Lancet Infect Dis 14(2):140-145.
14. Meyer B, et al. (2014) Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis 20(4):552-559.
15. Alagaili AN, et al. (2014) Middle East respiratory syndrome coronavirus infection in dromedary camels in saudi arabia. MBio 5(2):e00884-e00814.
16. Eckerle I, et al. (2014) Replicative Capacity of MERS Coronavirus in Livestock Cell Lines. Emerg Infect Dis 20(2):276-279.
17. Müller MA, et al. (2012) Human coronavirus EMC does not require the SARS-coro-navirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 3(6):e00515-e00512.
18. Hofmann H, et al. (2004) S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 78(12):6134-6142.
19. Chan KH, et al. (2013) Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluo-rescent and neutralizing antibody tests. J Infect 67(2):130-140.
20. Gierer S, et al. (2013) The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87(10):5502-5511.
21. Raj VS, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251-254.
22. Lu G, et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227-231.
23. Wang N, et al. (2013) Structure of MERS-CoV spike receptor-binding domain com-plexed with human receptor DPP4. Cell Res 23(8):986-993.
24. Falzarano D, et al. (2013) Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19(10):1313-1317.
25. Agnihothram S, et al. (2014) Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis 209(7):995-1006.
26. Du L, et al. (2013) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: Implication for developing therapeutics and vaccines. PLoS ONE 8(12): e81587.
27. Song F, et al. (2013) Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87(21):11950-11954.
28. Marasco WA, Sui J (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25(12):1421-1434.
29. Gould LH, et al. (2005) Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 79(23):14606-14613.
30. Kashyap AK, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105(16):5986-5991.
31. Traggiai E, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 10(8): 871-875.
32. Corti D, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044):850-856.
33. Throsby M, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3(12):e3942.
34. Sui J, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16(3):265-273.
35. Sui J, et al. (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101(8):2536-2541.
36. Mou H, et al. (2013) The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 87(16):9379-9383.
37. Sui J, et al. (2008) Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog 4(11):e1000197.
38. Wrammert J, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195):667-671.
39. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705-742.
40. Wu X, et al.; NISC Comparative Sequencing Program (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049): 1593-1602.
41. Chan CH, Hadlock KG, Foung SK, Levy S (2001) V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97(4):1023-1026.
42. Huang CC, et al. (2004) Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA 101(9):2706-2711.
43. Boyd SD, et al. (2010) Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J Immunol 184(12):6986-6992.
44. Watson CT, Breden F (2012) The immunoglobulin heavy chain locus: Genetic variation, missing data, and implications for human disease. Genes Immun 13(5):363-373.
45. Farci P, et al. (2010) B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci USA 107(19):8766-8771.
46. Assiri A, et al.; KSA MERS-CoV Investigation Team (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369(5):407-416.
47. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM (2013) Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 368(26):2487-2494.
48. Rani M, et al. (2012) Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J Virol 86(17):9113-9121.
49. Rockx B, et al. (2010) Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 201(6):946-955.
50. Cotten M, et al. (2013) Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive genomic study. Lancet 382(9909): 1993-2002.
51. Bermingham A, et al. (2012) Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 17(40):20290.
52. Cotten M, et al. (2013) Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 19(5):736-42B.
53. Public Health England, ISARIC (2013) Treatment of MERS-CoV: Decision Support Tool. Clinical Decision Making Tool for Treatment of MERS-CoV v.1.1. Available at www. hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317139281416. Accessed April 11, 2014.
54. ter Meulen J, et al. (2006) Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3(7): e237.
55. Bakker AB, et al. (2008) First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26(47):5922-5927.
56. Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2(3): 347-356.
57. Taube R, et al. (2008) Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS ONE 3(9):e3181.
58. Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J (2000) Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 18(6):649-654.
59. Xu C, Sui J, Tao H, Zhu Q, Marasco WA (2007) Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol 179(4):2408-2418.
60. Rockx B, et al. (2008) Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol 82(7):3220-3235.